Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
As previously reported, British Columbia, Alberta, and New Brunswick have all launched biosimilar initiatives which require that patients switch from certain reference biologics to biosimilars for certain indications.
As previously reported, British Columbia, Alberta, and New
Brunswick have all launched biosimilar initiatives which require
that patients switch from certain reference biologics to
biosimilars for certain indications. On May 18, 2021,
Québec announced that, subject to exceptions,
patients who use a reference biologic for which one or more
biosimilars are available will have to switch, under the
supervision of their doctor, to a biosimilar drug by April 12,
2022. According to the announcement, this shift will result in
annual savings of over $100 million dollars. Québec's
website on biosimilar drugs includes a section on the current situation regarding reimbursement.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
